Cell-type-specific responses to chemotherapeutics in breast cancer

Cancer Research

Volumn 64, Issue 12, 2004, Pages 4218-4226

  Troester, Melissa A ^a   Hoadley, Katherine A ^a,b   Sørlie, Therese ^c   Herbert, Brittney Shea ^d   Børresen Dale, Anne Lise ^c   Lønning, Per Eystein ^e   Shay, Jerry W ^f   Kaufmann, William K ^a,b   Perou, Charles M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; PROTEIN P21;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DIFFERENTIATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA MICROARRAY; DNA RESPONSIVE ELEMENT; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MITOMYCIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANS-ACTIVATION (GENETICS);

EID: 3042655539     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0107     Document Type: Article

References (42)

1. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst (Bethesda) 1998;90:1346-60.
2. Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-4.
3. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-47.
4. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature (Lond) 2000;406:747-52.
5. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
6. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature (Lond) 2002;415:530-6.
7. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
8. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-8.
9. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-35.
10. Hughes TR, Marton MJ, Jones AR, et al. Functional discovery via a compendium of expression profiles. Cell 2000;102:109-26.
11. Gasch AP, Spellman PT, Kao CM, et al. Genomic expression programs in the response of yeast cells to environmental changes. Mol Biol Cell 2000;11:4241-57.
12. Heinloth AN, Shackelford RE, Innes CL, et al. Identification of distinct and common gene expression changes after oxidative stress and gamma and ultraviolet radiation. Mol Carcinog 2003;37:65-82.
13. Wang HC, Federoff S. Banding in human chromosomes treated with trypsin. Nat New Biol 1972;235:52-4.
14. Van Ewijk PH, Hoekstra JA. Calculation of the EC50 and its confidence interval when subtoxic stimulus is present. Ecotoxicol Environ Saf 1993;25:25-32.
15. Tusher V, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21.
16. Geisler S, Borresen-Dale AL, Johnsen H, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003;9:558-8.
17. Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-12.
18. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8.
19. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol 1999;303:179-205.
20. Whitfield ML, Sherlock G, Saldanha AJ, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002;13:1977-2000.
21. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999;96:9212-7.
22. Bernal JA, Luna R, Espina A, et al. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 2002;32:306-11.
23. Kimura M, Kotani S, Hattori T, et al. Cell cycle-dependent expression and spindle pole localization of a novel human protein kinase, Aik, related to Aurora of Drosophila and yeast Ip11. J Biol Chem 1997;272:13766-71.
24. Kufer TA, Sillje HH, Korner R, Gruss OJ, Meraldi P, Nigg EA. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol 2002;158:617-23.
25. Liu G, Chen X. The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 2002;21:7195-204.
26. Park WY, Hwang CI, Im CN, et al. Identification of radiation-specific responses from gene expression profile. Oncogene 2002;21:8521-8.
27. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM. Id proteins in cell growth and tumorigenesis. Cancer Cell 2003;3:525-30.
28. Ma Y, Hendershot LM. The unfolding tale of the unfolded protein response. Cell 2001;107:827-830.
29. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997;15:537-47.
30. Korn EL, McShane LM, Troendle JF, Rosenwald A, Simon R. Identifying prepost chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim. Br J Cancer 2002;86:1093-6.
31. Smith GH, Chepko G. Mammary epithelial stem cells. Microsc Res Tech 2001;52:190-203.
32. Pechoux C, Gudjonsson T, Ronnov-Jessen L, Bissell MJ, Petersen OW. Human mammary luminal epithelial cells contain progenitors to myoepithelial cells. Dev Biol 1999;206:88-99.
33. Ross DT, Perou CM. A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers 2001;17:99-109.
34. Meyer KM, Hess SM, Tlsty TD, Leadon SA. Human mammary epithelial cells exhibit a differential p53-mediated response following exposure to ionizing radiation or UV light. Oncogene 1999;18:5795-805.
35. Herbert BS, Wright WE, Shay JW. Telomerase and breast cancer. Breast Cancer Res 2001;3:146-9.
36. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
37. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer [see comments]. Nat Genet 2000;24:236-44.
38. Weigel AL, Handa JT, Hjelmeland LM. Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med 2002;33:1419-32.
39. Morgan KT, Ni H, Brown HR, et al. Application of cDNA microarray technology to in vitro toxicology and the selection of genes for a real-time RT-PCR-based screen for oxidative stress in Hep-G2 cells. Toxicol Pathol 2002;30:435-51.
40. Sesto A, Navarro M, Burslem F, Jorcano JL. Analysis of the ultraviolet B response in primary human keratinocytes using oligonucleotide microarrays. Proc Natl Acad Sci USA 2002;99:2965-70.
41. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41.
42. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.